Workup and Management of Elevated Testosterone in Postmenopausal Women
In a postmenopausal woman with elevated testosterone, you must urgently exclude androgen-secreting tumors of the ovary or adrenal gland, which are rare but life-threatening causes that require immediate surgical intervention.
Initial Assessment Priority
The critical first step is determining the degree of testosterone elevation and associated clinical features, as these guide the urgency and extent of workup 1, 2.
Red Flags Requiring Urgent Evaluation
Look specifically for:
- Rapid onset or progression of symptoms (weeks to months rather than years)
- Virilization signs: clitoromegaly, deepening voice, increased muscularity, male-pattern baldness
- Severe hirsutism: particularly if sudden or worsening
- Testosterone levels in male range (typically >150-200 ng/dL or >5.2-6.9 nmol/L)
- Palpable abdominal or pelvic mass
These features significantly increase the likelihood of an androgen-secreting tumor, which occurs in approximately 1-3 per 1000 patients with hyperandrogenism but represents a critical diagnosis not to miss 1.
Diagnostic Workup Algorithm
Step 1: Confirm and Quantify Hyperandrogenism
Measure early morning (before 10 AM) total testosterone using a reliable assay method 3, 4. Mass spectrometry is the gold standard, as immunoassays can be unreliable at low levels 4.
If total testosterone is elevated, obtain:
- DHEAS (dehydroepiandrosterone sulfate): DHEAS >600 µg/dL (>16,000 nmol/L) suggests adrenal source and mandates immediate adrenal imaging 4
- Free testosterone or calculate free testosterone if total testosterone is borderline
- SHBG (sex hormone-binding globulin): Often decreased in metabolic syndrome, affects interpretation of total testosterone 4
- Androstenedione: May be elevated when testosterone is borderline 4
Step 2: Exclude Medication-Induced Causes
Review medications carefully:
- Anabolic steroids (consider in athletes, patients with sexual dysfunction)
- Valproic acid (only anticonvulsant that raises testosterone) 3
- Danazol
- Testosterone products (prescribed or over-the-counter supplements)
Step 3: Rule Out Other Endocrinopathies
Based on clinical suspicion, assess for 3:
- Cushing syndrome: If central obesity, striae, easy bruising, proximal weakness present
- Hyperprolactinemia: Measure prolactin
- Thyroid dysfunction: TSH
- Acromegaly: If coarse features, enlarged hands/feet present
- Congenital adrenal hyperplasia (late-onset): Early morning 17-hydroxyprogesterone if high-risk ethnicity (Ashkenazi Jewish, Hispanic, Slavic) 3
Step 4: Imaging Studies
The imaging approach depends on testosterone level and DHEAS:
If DHEAS >600 µg/dL:
If testosterone markedly elevated (>150-200 ng/dL) with normal/mildly elevated DHEAS:
- Transvaginal ultrasound as initial test
- Pelvic MRI if ultrasound inconclusive or high suspicion for ovarian tumor 1, 2
- Consider abdominal MRI to evaluate both adrenals and ovaries simultaneously 5
Important caveat: Imaging may be falsely negative in up to 50% of cases of ovarian hyperthecosis and some small androgen-secreting tumors 6, 5. A negative imaging study does NOT exclude a tumor.
Differential Diagnosis in Postmenopausal Women
The most common causes in descending order of frequency 1, 7, 2:
- Ovarian hyperthecosis: Non-neoplastic ovarian androgen overproduction, often associated with insulin resistance
- Polycystic ovary syndrome (PCOS): May worsen or become apparent after menopause
- Ovarian androgen-secreting tumors: Sertoli-Leydig cell tumors, thecomas, granulosa cell tumors
- Adrenal adenomas or carcinomas: Less common than ovarian but more likely malignant
- Late-onset congenital adrenal hyperplasia
- Iatrogenic: Exogenous androgen use
Management Strategy
If Tumor Suspected (High Testosterone, Virilization, or Positive Imaging)
Surgical removal is the definitive treatment 1. Refer urgently to gynecologic oncology (for ovarian) or endocrine surgery (for adrenal).
If No Tumor Identified but Significant Hyperandrogenism Persists
For patients who are poor surgical candidates or imaging-negative:
GnRH agonist therapy (leuprolide) is the most effective medical management for ovarian-source hyperandrogenism 6, 5. This approach:
- Dramatically reduces testosterone levels within 1 month
- Confirms ovarian source if effective
- Can be used long-term in non-surgical candidates
Important limitations:
- Causes significant menopausal symptoms (hot flashes, mood changes, sleep disturbance) that may lead to discontinuation 5
- Does not definitively exclude tumor (rare cases of gonadotropin-responsive tumors exist) 6
- Expensive and often not covered by insurance for this indication 5
Alternative/adjunctive therapies:
- Spironolactone (antiandrogen): For mild-moderate hirsutism
- Finasteride: 5α-reductase inhibitor for hirsutism
- Cosmetic measures: Laser hair removal, electrolysis
If Mild Elevation Without Concerning Features
Monitor clinically and biochemically every 3-6 months. Worsening symptoms or rising testosterone levels mandate complete re-evaluation with imaging 2.
Critical Pitfalls to Avoid
- Do not dismiss elevated testosterone as "normal aging" in postmenopausal women—this requires evaluation 1, 2
- Do not rely solely on imaging—negative imaging does not exclude tumor or hyperthecosis 6, 5
- Do not use unreliable testosterone assays—insist on mass spectrometry or high-quality immunoassays from specialty laboratories 3, 4
- Do not forget to check DHEAS—this is critical for localizing the source 4
- Do not assume PCOS—while common in premenopausal women, in postmenopausal women with new-onset hyperandrogenism, tumor must be excluded first 1
Long-term Considerations
Elevated testosterone in postmenopausal women is associated with increased cardiovascular risk, insulin resistance, and metabolic syndrome 1, 2. Even if no tumor is found, addressing hyperandrogenism improves quality of life and may reduce long-term metabolic complications 7.
The evidence base for postmenopausal hyperandrogenism is limited, with most guidelines extrapolated from premenopausal women 3. The recent literature emphasizes the importance of not missing tumors while recognizing that most cases are non-neoplastic and can be managed medically if surgery is not feasible 1, 6, 5, 2.